Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07855757) titled 'Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant Ascites' on Sept. 28.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Zhejiang Cancer Hospital
Condition:
Gastric Cancer (GC)
Peritoneal Metastases From Gastric Cancer
Ascites, Malignant
Intervention:
Drug: Retlirafusp Alfa + SOX + Intraperitoneal Nab-Paclitaxel
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: June 1, 2026
Target Sample Size: 5
Coun...